c-Jun N-terminal kinase pathways in diabetes

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 12, 2008, Pages 2702-2706

  Yang, Ruojing ^a   Trevillyan, James M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Insulin resistance; JNK; Lipid; Type 2 diabetes

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; INFLIXIMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PEPTIDE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SALICYLIC ACID DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CELL MEMBRANE PERMEABILITY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; GENE DISRUPTION; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RNA INTERFERENCE; SHORT SURVEY;

ANIMALS; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MODELS, BIOLOGICAL;

MUS;

EID: 51449093967     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.06.012     Document Type: Short Survey

References (20)

1. Bain J., McLauchlan H., Elliott M., and Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 371 (2003) 199-204
2. Bennett B.L., Satoh Y., and Lewis A.J. JNK: a new therapeutic target for diabetes. Curr Opin Pharmacol 3 (2003) 420-425
3. Bogoyevitch M.A., and Arthur P.G. Inhibitors of c-Jun N-terminal kinases-JuNK no more?. Biochim Biophys Acta 1784 (2008) 76-93
4. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-252
5. Drosatos K., Sanoudou D., Kypreos K.E., Kardassis D., and Zannis V.I. A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. J Biol Chem 282 (2007) 19556-19564
6. Gonzalez-Gay M.A., De Matias J.M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., Martin J., et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24 (2006) 83-86
7. Hirosumi J., Tuncman G., Chang L., Görgün C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
8. Kaneto H., Nakatani Y., Miyatsuka T., Kawamori D., Matsuoka T.A., Matsuhisa M., et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 10 (2004) 1128-1132
9. Lin J., Yang R., Tarr P.T., Wu P.H., Handschin C., Li S., et al. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120 (2005) 261-273
10. Liu G., and Rondinone C.M. JNK: bridging the insulin signaling and inflammatory pathway. Curr Opin Investig Drugs 6 (2005) 979-987
11. Manning A.M., and Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov 2 (2003) 554-565
12. Mooney L.M., and Whitmarsh A.J. Docking interactions in the c-Jun N-terminal kinase pathway. J Biol Chem 279 (2004) 11843-11852
13. Nakatani Y., Kaneto H., Kawamori D., Hatazaki M., Miyatsuka T., Matsuoka T.A., et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279 (2004) 45803-45809
14. Ricci R., Sumara G., Sumara I., Rozenberg I., Kurrer M., Akhmedov A., et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 306 (2004) 1558-1561
15. Szczepankiewicz B.G., Kosogof C., Nelson L.T., Liu G., Liu B., Zhao H., et al. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem 49 (2006) 3563-3580
16. Tuncman G., Hirosumi J., Solinas G., Chang L., Karin M., and Hotamisligil G.S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A 103 (2006) 10741-10746
17. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 115 (2005) 1111-1119
18. Yang R., Wilcox D.M., Haasch D.L., Jung P.M., Nguyen P.T., Voorbach M.J., et al. Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J Biol Chem 282 (2007) 22765-22774
19. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293 (2001) 1673-1677
20. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787